Effectiveness of rituximab for chemotherapy-resistant multiple tumoral B-LPD in a haemopoietic stem cell recipient [4]

British Journal of Haematology

Volumn 117, Issue 3, 2002, Pages 771-772

  Imashuku, Shinsaku ^a,b   Naya, Mayumi ^b   Tamura, Shinichi ^b   An, Byongmun ^b   Teramura, Tomoko ^a   Kobayashi, Mijako ^a   Nomura, Kenichi ^a   Taniwaki, Masafumi ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO CITY HOSPITAL   (Japan)

Author keywords

Epstein Barr virus; Post transplant lymphoproliferative disorder; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

APLASTIC ANEMIA; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CHEMOTHERAPY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LYMPHOPROLIFERATIVE DISEASE; NEEDLE BIOPSY; PRIORITY JOURNAL; RECIPIENT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

EID: 0036098731     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.34854.x     Document Type: Letter

References (4)

1. Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation
2. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children
3. Quantitative analysis of cell-free Epstein-Barr virus genome copy numbers in patients with EBV-associated hemophagocytic lymphohistiocytosis
4. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma